BRCA-1/2-test (age ≥ 35; family case history) |
5 400 $/QALY |
Raloxifen to reduce risk (age 55) |
22 000 $/QALY |
Letrozole vs. anastrozole (postmenopausal, HR+) |
26 000 $/QALY |
Lapatinib plus capecitabine vs. capecitabine |
170 000 $/QALY |
Yearly screening by MRI vs. mammography (BRCA1) |
210 000 $/QALY |
Bevacizumab plus paclitaxel vs. paclitaxel |
280 000 $/QALY |
Partial breast irradiation vs. whole breast irradiation (stage I, ER+, postmenopausal) |
730 000 $/QALY |
Digital mammography screening vs. film (age ≥ 40) |
930 000 $/QALY |